NextCure (id:8430 NXTC)
1.19 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 9:09:17 PM)
Exchange closed, opens in 12 hours 20 minutes
About NextCure
Market Capitalization 36.13M
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
| Headquarters (address) |
9000 Virginia Manor Road Beltsville 20705 MD United States |
| Phone | 240 399 4900 |
| Website | https://www.nextcure.com |
| Employees | 82 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | NXTC |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.03 - 2.57 |
| Market Capitalization | 36.13M |
| P/E trailing | -0.529 |
| P/E forward | -0.902 |
| Price/Book | 0.315 |
| Beta | 0.791 |
| EPS | -2.10 |
| EPS United States (ID:6, base:3402) | 24.23 |